ArticleBreast cancer (Dove Medical Press)2018

A combination of p53-activating APR-246 and phosphatidylserine-targeting antibody potently inhibits tumor development in hormone-dependent mutant p53-expressing breast cancer xenografts.

Yayun Liang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.